Loading...
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
BACKGROUND: Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. OBJECTIVES: To compare early and complete skin clearance by the IL‐17A inhibitor ixekizumab vs. the IL‐23p19 inhibitor gus...
Na minha lista:
| Udgivet i: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7317420/ https://ncbi.nlm.nih.gov/pubmed/31887225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18851 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|